Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWilmington Regulatory News (WIL)

Share Price Information for Wilmington (WIL)

Share Price is delayed by 15 minutes
Get Live Data
266.00    0.00 (0.00%)
Bid:
254.00
Ask:
280.00
Spread: 26.00 (10.236%)
Market Cap: £238.22m
WIL Live PriceLast checked at - London Stock Exchange

Intraday Wilmington Share Chart

AGM and Q1 Trading update

3 Nov 2016 07:00

RNS Number : 1614O
Wilmington PLC
03 November 2016
 

3 November 2016

 

Wilmington plc

 

AGM and Q1 Trading update

 

Wilmington plc ("Wilmington" or "the business"), the knowledge leader in Risk & Compliance, Finance, Legal, and Insight announces its trading update for the three month period to 30 September 2016 with comments reflecting trading to-date. This statement is also being made at the Group's Annual General Meeting being held today.

 

Trading Update

As we reported, Wilmington has had a mixed start with good growth from Risk & Compliance and the Insight division but that was offset by a weaker performance from Legal and Finance.

 

Revenue was up 8.5% (4% constant currency) compared to the first three months of 2015/16 helped by translation gains from our non-sterling revenue and from contributions from acquisitions. Profits were down compared to last year due to a combination of timing with the movement of one large compliance program and due to the slow start for AMT previously reported as well as planned investments.

 

As previously highlighted, significant investments are being made in people and in establishing new offices in Singapore, Barcelona and in the US. In particular we have accelerated investments in our Compliance, Insurance and Healthcare businesses. Whilst the benefits of these investments are expected to be seen in the second half of this financial year it will result in adjusted profits for the first six months being maintained at around the levels seen last year.

 

Acquisitions made in 2015/16 and our latest acquisition, SWAT, continue to perform well and we expect SWAT to be earnings enhancing in this current financial year.

 

Overall, Wilmington is on track to deliver against expectations for the full year.

 

Operational Review

Wilmington Risk & Compliance: 

Risk & Compliance delivered strong revenue growth in the period. The compliance business continues to enjoy significant demand for its accredited face to face training in both public events and bespoke in-house assignments. Growth would have been even stronger but we decided to delay a large training program worth over £0.5m by two months to capture additional demand. To strengthen our infrastructure and to support the expected continued growth in revenue from compliance, we have

set up our US operation and have recruited a number of senior positions over the last three months. At the same time we have made initial exploratory investments in the next generation of Axco products and services. Compliance Week had a disappointing start to the year and we have seen weaker than expected demand for our Annual European Compliance event.

 

Wilmington Finance: 

Finance revenue was marginally down overall compared to a very strong 2015 comparator period, benefitting from currency gains and from the acquisition of SWAT offsetting the one off benefit in 2015 of the additional UK fiscal budget and the impact of the weakness in AMT. As previously reported AMT had a weak start mainly due to the competition issues previously highlighted but also due to some softening of investment bank training assignments in the Asia Pacific region. The impact of this reduced high margin AMT revenue has had a material impact on the division's profits.

 

Wilmington Legal:

Challenging market conditions remain in the Law for Lawyers part of the Legal division and the Legal division overall experienced a weaker than expected first quarter. This was a result largely of continued reduced demand for face to face CLE training and conferences. The overall revenue decline was offset by the lower cost base implemented last year and we saw a welcome overall improvement in contribution from the division.

 

Wilmington Insight: 

The division has had a good start with revenue up on last year overall and up on an underlying basis. Healthcare has enjoyed good growth driven by the higher margin multi product analytical assignments from NHiS and Evantage. The trends seen last year in non-healthcare data suppression and the charities businesses have continued as expected.

 

SWAT

SWAT was acquired on 19 July 2016 and had an excellent first quarter recording a profit contribution on revenue of £1.0m.

 

Cash Flow

Net debt as at 30 September 2016 was £38.7m (2015: £36.3m) reflecting the acquisition of SWAT for £1.9m, the deferred consideration for FRA of £1.1m paid in July 2016 and the effects of retranslating US dollar debt into Sterling of £0.5m.

 

Unrealised exchange loss

As previously reported, Wilmington has entered into a number of currency sale agreements to sell surplus US Dollars and Euros for Sterling in line with its stated treasury policy. The average rate of these contracts is $1.46 for $10.0m and €1.26 for €3.5m for settlement in the second half of 2016/17.

As required under IFRS accounting standards these contracts will be revalued at 31 December 2016 and the resultant unrealised non-cash difference between the value at 30 June 2016 and 31 December 2016 will be charged to the Income statement for the six months to 31 December 2016. Depending on exchange rates this non-cash unrealised charge could be material.

 

Outlook

The overall trading outlook has not changed since the full year 2016 results announcement although we may see a material unrealised non cash exchange loss reported at the end of December 2016. This exchange loss should reverse to some extent in the second half of the year when those currency contracts are fulfilled.

 

We continue to see the trends of tighter regulatory control and more complex legislation being implemented in most of our key markets, which in turn is driving demand for many of our products and services. We have also continued to invest heavily as planned in our Compliance business which is providing the infrastructure and support for anticipated future growth and are looking to develop new products and markets for Axco. These investments have been accelerated and will impact the first six months profits but are necessary to capture expected longer term revenue generating opportunities. Overall, Wilmington is on track to deliver against expectations for the full year.

 

-End-

 

For further information, please contact:

 

 

Wilmington plc

Pedro Ros, Chief Executive Officer

Tony Foye, Chief Financial Officer

 

FTI Consulting

Charles Palmer / Emma Appleton

 

020 7422 6800

 

 

 

020 3727 1000

 

Notes to Editors

 

Wilmington plc is the recognised knowledge leader and partner of choice for information, education and networking in Risk & Compliance, Finance and Legal as well as the Insight leader in a number of chosen industries. Capitalised at approximately £230 million, Wilmington floated on the London Stock Exchange in 1995.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEALFAEFKKFFF
Date   Source Headline
17th Apr 202611:20 amRNSHolding(s) in Company
15th Apr 20263:56 pmRNSBoard changes
15th Apr 202611:21 amRNSSave As You Earn Options
11th Mar 202611:00 amRNSDirector Declaration
11th Mar 202611:00 amRNSDirector Declaration
26th Feb 20267:00 amRNSHalf-year Financial Report
11th Feb 20262:44 pmRNSNotice of half year-end results
21st Jan 202611:19 amRNSNotice of Half Year Results
23rd Dec 20257:00 amRNSAppointment of Joint Corporate Broker
23rd Dec 20257:00 amRNSAppointment of Joint Corporate Broker
5th Dec 20259:56 amRNSAcquisition of Conversia completed
28th Nov 20254:23 pmRNSDirector/PDMR Shareholding
28th Nov 202511:22 amRNSAcquisition of Conversia cleared to complete
25th Nov 20259:19 amRNSResult of AGM
10th Nov 20255:54 pmRNSDirectorate change
1st Oct 20252:51 pmRNSDirector/PDMR Shareholding
1st Oct 20252:49 pmRNSDirector/PDMR Shareholding
1st Oct 20257:00 amRNSDirector/PDMR Shareholding
1st Oct 20257:00 amRNSTotal Voting Rights
22nd Sep 202512:48 pmRNSDirector/PDMR Shareholding- Replacement
22nd Sep 202511:52 amRNSDirector/PDMR Shareholding
22nd Sep 20257:00 amRNSFinancial results for the year ended 30 June 2025
5th Sep 202510:58 amRNSHolding(s) in Company
1st Sep 20257:00 amRNSNotice of year-end results
29th Aug 202511:07 amRNSHolding(s) in Company
12th Aug 20257:03 amRNSProposed acquisition of Conversia
12th Aug 20257:00 amRNSDirector Declaration
1st Aug 20257:00 amRNSAppointment of Joint Corporate Broker
30th Jul 20257:00 amRNSStatement in relation to a potential acquisition
23rd Jul 20257:00 amRNSTrading Statement
1st Jul 20257:00 amRNSTotal Voting Rights
26th Jun 20259:00 amRNSDirector/PDMR Shareholding
13th Jun 20257:00 amRNSTransaction in Own Shares
12th Jun 20257:00 amRNSTransaction in Own Shares
11th Jun 20257:00 amRNSTransaction in Own Shares
9th Jun 20257:00 amRNSTransaction in Own Shares
6th Jun 20257:00 amRNSTransaction in Own Shares
5th Jun 20257:00 amRNSTransaction in Own Shares
4th Jun 20257:00 amRNSTransaction in Own Shares
3rd Jun 20257:00 amRNSTransaction in Own Shares
2nd Jun 20259:30 amRNSTotal Voting Rights
2nd Jun 20257:00 amRNSTransaction in Own Shares
30th May 20257:00 amRNSTransaction in Own Shares
29th May 20257:00 amRNSTransaction in Own Shares
28th May 20257:00 amRNSTransaction in Own Shares
27th May 20257:00 amRNSTransaction in Own Shares
23rd May 20257:00 amRNSTransaction in Own Shares
22nd May 20257:00 amRNSTransaction in Own Shares
21st May 20257:00 amRNSTransaction in Own Shares
20th May 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.